A new US tariff on branded pharmaceuticals has sparked concerns for Indian drugmakers, particularly regarding branded generics and CDMOs. Market expert Sandip Sabharwal favors auto stocks like Maruti and M&M, anticipating benefits from rupee depreciation. He also cautions against the current IPO rush, deeming valuations too high and preferring to remain on the sidelines.
Originally published by The Economic Times https://economictimes.indiatimes.com/markets